Yarrow supercritical extract exerts antitumoral properties by targeting lipid metabolism in pancreatic cancer

Lamia Mouhid1*, Marta Gómez de Cedrón1*, Elena García-Carrascosa1, Guillermo Reglero1,2, Tiziana Fornari2, Ana Ramírez de Molina1*

1 Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM + CSIC, Madrid, Spain, 2 Production and Characterization of Novel Foods Department, Institute of Food Science Research CIAL, CEI UAM + CSIC, Madrid, Spain

* These authors contributed equally to this work.
*ana.ramirez@imdea.org (ARDM); marta.gomezdecedron@imdea.org(MGDC)

Abstract

Metabolic reprogramming is considered a hallmark of cancer. Currently, the altered lipid metabolism in cancer is a topic of interest due to the prominent role of lipids regulating the progression of various types of tumors. Lipids and lipid-derived molecules have been shown to activate growth regulatory pathways and to promote malignancy in pancreatic cancer. In a previous work, we have described the antitumoral properties of Yarrow (Achillea Millefolium) CO2 supercritical extract (Yarrow SFE) in pancreatic cancer. Herein, we aim to investigate the underlaying molecular mechanisms by which Yarrow SFE induces cytotoxicity in pancreatic cancer cells. Yarrow SFE downregulates SREBF1 and downstream molecular targets of this transcription factor, such as fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). Importantly, we demonstrate the in vivo effect of Yarrow SFE diminishing the tumor growth in a xenograft mouse model of pancreatic cancer. Our data suggest that Yarrow SFE can be proposed as a complementary adjuvant or nutritional supplement in pancreatic cancer therapy.

Introduction

Pancreatic cancer is the second leading cause of cancer-related deaths worldwide. It is an aggressive malignancy with poor prognosis: the overall 5-year survival rate is less than 5%. Risk factors described to be linked with its development are obesity and chronic pancreatitis, but also tobacco smoking, heavy alcohol intake, unbalanced diets, or high red meat intake [1,2]. Given the absence of indicators of illness, it is often diagnosed at metastatic late stages. Although surgery remains the main beneficial treatment followed by chemotherapy and radiation, current therapies do not improve patient’s survival. Therefore, the development of effective therapeutic strategies targeting molecular alterations associated with pancreatic tumor growth and the resistance to apoptosis are needed to improve their survival.
In the last years, there has been a growing interest in the use of phytochemicals and dietary-derived compounds for prevention or for cancer treatment [3,4]. Thus, some of them have shown antitumoral properties in vitro and in vivo [4–6]. In this regard, there are some phytochemicals derived from natural sources, such as taxol and camptothecin, which are extensively used in clinics to treat several tumors [7,8]. Nevertheless, pancreatic cancer remains one of the most resistant tumor [9]. Current chemotherapy is based on the use of gemcitabine, 5-fluorouracil, irinotecan and/or oxaliplatin but new complementary approaches are required.

On the other hand, metabolic reprogramming is well-recognized as a hallmark of cancer [10] and thus, there is an increased interest for targeting its altered metabolism. Tumors display high rates of cell proliferation and they can acquire malignancy associated to stemness and invasive properties. Moreover, highly proliferative cells hold an exacerbated glucose uptake sustaining aerobic glycolysis (Warburg effect) for anabolic processes [11–13]. In addition, increased glutamine uptake and glutaminolysis support carbon and nitrogen backbones for anabolic purposes. Nitrogen, in addition to its role in protein and nucleotide biosynthesis, is crucial for the synthesis of glutathione and essential to maintain the redox homeostasis [12–14].

Cancer cells are also characterized by having an increased de novo fatty acid synthesis which contributes to the carcinogenic process and cancer cell survival. Metabolic fatty acid (FA) enzymes are essential for neoplastic growth as well as for the signaling of key tumorigenic pathways. During tumor development, lipid associated alterations include an increase in lipogenic enzymes expression such as fatty acid synthase (FASN), acetyl carboxylase (ACC), stearoyl-CoA desaturase (SCD), ATP citrate lyase (ACLY), and an increase in the synthesis and uptake of cholesterol. As a result, tumor cells can control membrane fluidity, which has an impact on intracellular oncogenic signaling pathways, and sharpens resistance to chemotherapeutics. In addition, the increased storage of lipid and cholesterol molecules into lipid droplets allows tumor cells to gain independence from the extracellular nutrient availability [15,16].

In this context, many authors have described alterations in expression of lipid metabolic genes, and their link with the development and prognosis in cancer [17,18]. Thus, targeting specific enzymes involved in fatty acid and cholesterol synthesis, or affecting genes involved in their transcriptional regulation could be a novel approach for cancer treatment [19,20].

Recently we have described the antitumoral properties of Achillea Millefolium derived extract, commonly known as Yarrow, obtained by Supercritical Fluid Technology (SFE), in pancreatic cancer cell lines [21]. Yarrow SFE diminishes cell viability of pancreatic cancer cells in a dose dependent manner, induces apoptosis and inhibits anchorage independent cell growth. Moreover, Yarrow SFE synergizes with 5-fluororacil (5-Fu) which is currently used in the clinics in pancreatic cancer treatment [22]. Herein, we identify Sterol Regulatory Element-Binding Transcription Factor 1 (SREBF1) as a molecular target of Yarrow SFE which is implicated, at least partially, in the antitumoral activities observed. Importantly, downstream molecular targets of SREBP1, such as FASN and SCD, are also diminished both at the transcriptional and post-transcriptional levels. These alterations would affect intracellular lipid homeostasis which also correlate with the inhibition of invasiveness properties of pancreatic cancer cells.

Importantly, we also demonstrate the in vivo effect of Yarrow SFE diminishing the tumor growth in a xenograft model of pancreatic cancer. Based on these results, Yarrow supercritical extract could be proposed as a complementary adjuvant in pancreatic cancer therapy.

Methods

Yarrow extract

Yarrow SFE was obtained by CO₂ supercritical fluid extraction (Thar Technology, model SF2000). Briefly, a CO₂ flux of 70 g/min, 140 bar and 40°C for 180 minutes was applied to 400
g of dried and grounded Yarrow in a 2L cylinder. The resulting extract was collected with absolute ethanol, and the dissolvent was removed using a rotavapor at low temperature (30˚C).

The extract contains volatile oils which comprises monoterpenes such as eudesmol (11.19%) and borneol (16.28%) as major compounds, and sesquiterpenes as caryophyllene (4.90%), α-cadinol (8.22%), α-bisabolol (2.73%), among others [21].

**Cell culture**

Pancreatic cancer cells MIA PaCa-2 and PANC-1 were purchased from American Type Culture Collection (Manassas, VA) and were cultured in DMEM media (2 mM glutamine) and 10% fetal bovine serum (LONZA Iberica, S.A) in 5% CO₂ atmosphere at 37˚C and 95% humidity. 5 x 10⁶ cells were seeded in M6 multiwell plates for microarray assays and in a p60 culture dishes to isolate proteins for WB analysis and mRNA for qPCR.

**RNA isolation and gene expression assay**

MIA PaCa-2 and PANC-1 cells were plated and after an overnight incubation, cells were treated with 30 and 70 μg/mL of Yarrow extract for 48 hours. Non-treated cells were kept as controls. Total RNA was isolated from each condition with RNeasy Mini Kit (Qiagen Iberica) following manufacturer’s instructions. RNA quality and quantity were checked by UV spectroscopy (Nanodrop 2000 Spectrophotometer, Thermo Scientific, Waltham).

RNA extracted from MIA PaCa-2 was subsequently used for a comparative microarray gene expression analysis between non-treated and 30 and 70 μg/mL Yarrow treated cells. The analysis was performed at the Genomic Service Facilities at the National Center of Biotechnology (CNB-Madrid, Spain). RNA integrity was first determined using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNAs were then reverse transcribed and fluorescently tagged using the one color Low Input Quick Amp Labeling Kit (Agilent Technologies), according to manufacturer’s instructions. The complementary RNAs were hybridized in an Agilent Sure Print G3 Human 8x60 K (Whole Human Genome Microarray Kit) platform, using the one-color gene expression system as described by the manufacturer (Agilent Technologies).

**Quantitative real-time polymerase chain reaction (qPCR)**

Same amounts for each RNAs samples were reverse transcribed by a high Capacity cDNA Archive Kit (applied Biosystems) for 2 hours at 37˚C. To determine gene expression, Real-time-qPCRs were performed on the 7900HT-Real-Time PCR System (Applied Biosystems, Foster City, CA) using the TaqMan gene expression assays. The probe sets were Hs01056222, Hs01682761, Hs01088691, Hs00607129, Hs 1597989, Hs99999901_s1 for FASN, SCD, SREBF1, HSPA-5, ASS1 and 18s, respectively. For the isoforms SREBP1-a and SREBP1-c, the primers used to quantify their expression were hSREBP-1a (Fw: GAGGGGTAGGGCAACGGCCT; Rv: CATGCTTTCGAAAGCCGAGGGTTCACC) and hSREBP-1c (Fw: TCAGGGGAGGGCTTTTGAGCCAG; Rv: CATGCTTTCGATGTCGGTCAG). The relative expression quantity for each gene (RQ) was determined following the 2-ΔΔCt Livak method [23].

RQ Manager Software and Expression Suite Software (Applied Biosystems) were used to calculate the relative expression of each gene.

**Intracellular cholesterol and neutral lipid content**

To determine the total intracellular cholesterol, the assay was carried out following the instructions of Cholesterol Detection Kit (cell-based) (BioVision Inc, San Francisco, USA). Briefly,
cells were cultured with 50 and 70 μg/mL Yarrow for 48 hours before to be extracted with 200 μL of chloroform: Isopropanol: NP-40 (7:11:0.1) in a micro-homogenizer. The lipid fraction was collected and mingled with a cholesterol enzyme mix (which includes cholesterol esterase), and the absorbance of the resultant colorimetric assay was measured at 570 nm.

Quantification of neutral lipid content was done by mean of Bodipy staining. As a brief description, cells were treated with 2 μM BODIPY staining solution (BODIPY 493/503, Invitrogen) in PBS for 15 min at 37˚C and fixed with 4% paraformaldehyde (PFA). Images were obtained with a Leica DM IL microscope, 40X Plan Fluotar objective and registered using Leica Application Suite (LAS).

**Immunoblot analysis**

After 48 hours incubation with Yarrow SFE, cells were washed and detached using trypsin. Protein lysates were obtained with Laemmli buffer (60 mM Tris-HCl, 10% glycerol 2% SDS) and centrifuged at 5000 rpm for 5 minutes. After quantification (BCA-Piercing), denaturated protein samples were separated through a 4–15% Mini-Protein TGX Precast Protein Gel (BioRad) and transferred onto a nitrocellulose membrane using Trans-Blot Turbo Transfer System (BioRad). Membranes were incubated in 5% non-fat dried milk PBS (1% Tween-20) at room temperature for 1 hour and then incubated overnight with primary antibodies against FASN (Cell Signaling) and SCD (kindly provided by Dr Demoulin [24]. α-tubulin (Sigma-Aldrich) was used as a loading control.

**Invasion through matrigel**

To evaluate the effect of Yarrow SFE on invasiveness, MIA PaCa-2 cells were treated for 48 hours with different doses of Yarrow SFE. After discarding dead cells, a total of 2.2×10^4 alive ones were then maintained in 1% FBS DMEM (without extract) and seeded onto Matrigel-coated Transwell chambers (8.0 μm pore) (Corning Life Sciences). In the lower chamber, 700 μL of DMEM with 10% FBS were added as a chemo attractant. 48 hours later, inserts were washed twice with PBS and fixed with 4% paraformaldehyde prior to crystal violet staining. Cells that have invaded through Matrigel in four random fields were counted using a light microscope at ×10 magnification.

**Animals and tumor xenograft model**

All procedures were approved by the Animal Care and Use Committee of the Consejo Superior de Investigaciones Científicas (CSIC, Spain), and by the authority of the Comunidad of Madrid (PROEX112/17). Male Hsd: Athymic Nude-Foxn1nu nude mice (7 weeks old, weighing 26–31 g) were purchased from Envigo RMS (Spain). Mice were kept in a temperature and humidity-controlled environment, with 12 hours light/dark-cycle and had access to water and standard chow (Safe, D40 RMM. Proteins 15.2%, Fat: 3.2%, Minerals Ash: 4.4%, Fiber: 4.1%) ad libitum.

The xenograft model was obtained by injecting subcutaneously into the back loin 1,5 x10^6 MIA PaCa-2 cells diluted in DMEM: Matrigel (50:50). After 15 days, 8 animals received Yarrow SFE extract (1000 mg/Kg), diluted in corn oil (Sigma-Aldrich) in 150 μL as final volume. The treatment was administrated using an orogastric silicon-tube, three times per week for 15 days. Intragastrical administration of an equal volume of corn oil alone was given to 8 control animals.

Human endpoints were established if tumors had reached 1.6 cm^3 or more, or if there had been signs of ulceration, or mice had lost 20% or more of body weight, or if mice had presented piloerection, stereotyped or aggressive behaviors, pain indicative postures, lack of
activity and tremors or convulsions. Animals were daily monitored, assessing the room temperature and humidity, and their health by checking their behavior and general appearance. Body weight was measured weekly. The antitumor effect of Yarrow was monitored by estimating tumor volume (mm$^3$) and calculated as $(W^2 \times L) \times 0.52$, where $W$ is tumor width (in mm) and $L$ is tumor length (in mm).

Finally, animals were euthanized by cervical dislocation.

**Immunohistochemistry**

Immunohistochemistry was performed following standard protocols. Mouse monoclonal antibody against Ki-67 (IR626, DAKO) was used on tissue paraffin sections (4μm). Images were obtained through the Axio Scan Z1 (Zeiss). The quantification of Ki-67 positive cells was done with ZEN Lite 2.3 software (Zeiss).

**Statistical analysis**

Microarray gene expression data were obtained and analyzed using FIESTA software (version 1.0, http://bioinfogp.cnb.csic.es/tools/FIESTA; Centro Nacional de Biotecnología, Madrid, Spain). Statistical analyses were determined by the Limma package (linear models for microarray data) (Smyth, 2004), using a $p$-value $< 0.05$ as limit of significance. Overexpression and repression were considered from a minimum change of 2-fold of the non-treated cells (control).

RT-qPCR results were analyzed by using two-way ANOVA (Bonferroni post hoc test). Western Blot results were quantified by Image J and statistically analyzed by one-way ANOVA (Bonferroni post hoc test). One-way ANOVA was also used to determine differences in invasion and 3D-culture. Results of *in vivo* experiments were analyzed with t-student statistical analysis. Statistical differences were considered significant when $p$-value was $< 0.05$.

All the statistical analysis was performed with GraphPad Prim 6 statistical software.

**Results**

**Yarrow SFE downregulates the expression of the lipid metabolism-master regulator SREBF1**

In a previous work we have described that Yarrow SFE inhibits cell viability of MIA PaCa-2 and PANC-1 pancreatic cancer cell lines, with an induction of apoptotic cell death [22].

In order to identify the molecular targets implicated on the mechanism of action of Yarrow SFE, a comparative gene expression microarray (G2519F-026652 Human Gene Expression v2 4x44K Microarray) was performed (link to raw data: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124043). MIA PaCa-2 cells were treated with two different doses of Yarrow ($IC_{50}$: 31.45 ±8.56 μg/mL and 2x $IC_{50}$) for 48 hours. Genes whose expression was significantly altered at both concentrations ($p$-value $< 0.05$), with a minimum of 2-fold change overexpression or repression, compared to control non-treated cells (DMSO), are listed in **Table 1**.

SREBF1 (Sterol Regulatory Element Binding Transcription Factor), ASS1 (Argininosuccinate Synthase) and HSPA-5 (Homo Sapiens Heat Shock protein 5) were selected for further validation by RT-qPCR due to their known association with tumor processes and with pancreatic cancer development. As shown in **Fig 1**, Yarrow SFE significantly diminished the expression levels of SREBF1 in a 25% and 48% after 30 and 70 μg/m treatments respectively, compared to control cells (DMSO).
Sterol regulatory element binding proteins (SREBP) are master transcriptional regulators of the synthesis and uptake of lipids and cholesterol [80]. In mammals, there are two isoforms of SREBP proteins, SREBP1 and SREBP2. SREBP1 is mainly implicated in the expression of genes for de novo synthesis of fatty acids, meanwhile SREBP2 is dedicated to the regulation of genes involved in the synthesis and uptake of cholesterol. Nevertheless, SREBP1 and 2 significantly overlap in the regulation of lipid homeostasis [81,82].

SREBP1 has been found highly upregulated in several cancers. In humans, it includes, in turn, two isoforms: SREBP1c which regulates FA metabolism, and SREBP1a which is implicated in both fatty acid (FA) and cholesterol metabolism [81].

| Yarrow (μg/mL) | Genes | Fold Change | P-value (Limma) | Systematic Name | Description | Cancer Ref. | Pancreatic Cancer Ref. |
|---------------|-------|-------------|----------------|-----------------|-------------|-------------|-----------------------|
| 30            | ASS1  | -3.62       | 0.033          | NM_000050       | Homo sapiens argininosuccinate synthase 1, transcript variant 1 | [25–27]     | [28–30]                     |
| 70            |       | -4.38       | 0.0477         |                 |             |             |                       |
| 30            | CHD5  | 2.84        | 0.0036         | NM_015557       | Homo sapiens chromodomain helicase DNA binding protein 5 | [31–33]     | [34]                       |
| 70            |       | 2.40        | 0.0026         |                 |             |             |                       |
| 30            | CREBZF| 2.82        | 0.0017         | NM_001039618    | Homo sapiens CREB/ATF bZIP transcription factor, transcript variant 1 | [35,36]     | [37,38]                     |
| 70            |       | 2.08        | 0.0214         |                 |             |             |                       |
| 30            | CSTF3 | 2.08        | 0.0355         | NM_001033505    | Homo sapiens cleavage stimulation factor, transcript variant 2 | [39,40]     | [41–43]                     |
| 70            |       | 2.08        | 0.0269         |                 |             |             |                       |
| 30            | DHR5  | -2.78       | 0.0178         | NM_004753       | Homo sapiens dehydrogenase /reductase (SDR family) member 3 | [41,43]     | [44,45]                     |
| 70            |       | -2.52       | 0.0435         |                 |             |             |                       |
| 30            | HLA-G | -2.80       | 0.0415         | NM_002127       | Homo sapiens major histocompatibility complex, class I, G | [44,45]     | [46–49]                     |
| 70            |       | -3.58       | 0.0280         |                 |             |             |                       |
| 30            | HSPA5 | -2.44       | 0.0406         | NM_005347       | Homo sapiens heat shock 70kDa protein 5 glucose-regulated protein, 78kDa | [50–52]     | [46–49]                     |
| 70            |       | -2.51       | 0.0444         |                 |             |             |                       |
| 30            | ICAM5 | -2.05       | 0.0145         | NM_003259       | Homo sapiens intercellular adhesion molecule 5, telen cephalin | [53,54]     | [55,56]                     |
| 70            |       | -2.02       | 0.0196         |                 |             |             |                       |
| 30            | ING3  | 2.44        | 0.0035         | NM_019071       | Homo sapiens inhibitor of growth family, member 3 transcript variant 1 | [55,56]     | [57–59]                     |
| 70            |       | 2.03        | 0.0152         |                 |             |             |                       |
| 30            | MEF2D | -2.98       | 0.0144         | NM_005920       | Homo sapiens myocyte enhancer factor 2D, transcript variant 1 | [58,59]     | [60,61]                     |
| 70            |       | -2.18       | 0.0155         |                 |             |             |                       |
| 30            | PALM  | -2.21       | 0.0028         | NM_002579       | Homo sapiens paralemmin, transcript variant 1 | [61]        | [62]                        |
| 70            |       | -2.09       | 0.0271         |                 |             |             |                       |
| 30            | RAB11FIP1 | -2.06 | 0.0334 | NM_001002814 | Homo sapiens RAB11 family interacting protein 1 (class I), transcript variant 3 | [62]        |                       |
| 70            |       | -2.11       | 0.0448         |                 |             |             |                       |
| 30            | SERPINA3 | -3.01 | 0.0078 | NM_001085 | Homo sapiens serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 | [63,64]     |                       |
| 70            |       | -2.27       | 0.0061         |                 |             |             |                       |
| 30            | SHC1  | -2.21       | 0.0237         | NM_003029       | Homo sapiens SHC (Src homology 2 domain containing) transforming protein 1, transcript variant 2 | [65]        | [66]                        |
| 70            |       | -2.01       | 0.0359         |                 |             |             |                       |
| 30            | SKAP2 | -2.61       | 0.0149         | ENST00000345317 | Src kinase associated phosphoprotein 2 | [67,68]     | [69]                        |
| 70            |       | -2.08       | 0.0346         |                 |             |             |                       |
| 30            | SREBF1| -2.75       | 0.0004         | NM_001005291    | Homo sapiens sterol regulatory element binding transcription factor 1, transcript variant 1 | [70–74]     | [75,76]                     |
| 70            |       | -2.05       | 0.0064         |                 |             |             |                       |
| 30            | TRIM44| -2.13       | 0.0351         | NM_017583       | Homo sapiens tripartite motif containing 44 | [77–79]     |                       |
| 70            |       | -2.07       | 0.0371         |                 |             |             |                       |

https://doi.org/10.1371/journal.pone.0214294.t001
As individual functions of SREBPs are overlapped, we wanted to determine the effect of Yarrow SFE on the expression of the two SREBP1 isoforms. As shown in Fig 2A, RT-qPCR analysis showed that Yarrow SFE diminished the expression of SREBF1a and 1c similarly in a dose-dependent manner. On the other hand, the altered cholesterol homeostasis is frequently linked to the tumorigenic process and malignancy of tumors [83]. Considering that SREBP1a and SREBP2 share around 45% of homology at the protein level, we wonder if Yarrow SFE extract could affect the expression of SREBF2 in a similar manner it does with SREBF1. Treatments with Yarrow SFE did not show a significant affectation of the expression levels of SREBF2 neither in MIA PaCa-2 (Fig 2B) nor in PANC-1 (Fig 2C). Indeed, when we analyzed the intracellular cholesterol content, we did not found differences between Yarrow SFE treatments compared to control cells (S1 Fig), certainly due to the non-alteration of SREBP2 expression.

These results suggest that SREBP2 can maintain the cholesterol homeostasis in spite of the downregulation of SREBP1, where Yarrow SFE specifically targets the expression of SREBF1 transcription factor. Importantly, as the activity of SREBP1 is low in normal tissues and aberrantly increased in cancer pathogenesis [84], its inhibition has been considered a promising strategy for cancer treatment [75,82].

Yarrow SFE downregulates FASN and SCD downstream molecular targets of SREBP1

Multiple studies have revealed that oncogenic pathways such as PI3K/Akt signaling, which regulates glucose metabolism, and oncogenic Myc, which regulates glutamine metabolism, end up with the upregulation of SREBP1 to promote fatty acid synthesis [84–86].

Thus, SREBP1 connects oncogenic upregulation of glycolysis and/or glutaminolysis to lipogenesis [11], by inducing the expression of Fatty Acid Synthase (FASN) and the Stearoyl-CoA desaturase (SCD), among others. As we did not have observed any significant difference
regardless cholesterol levels, we wonder if lipogenic genes regulated by SREBP1, such as FASN and SCD, could be altered. Yarrow SFE treatments of MIA PaCa-2 cells for 48 hours downregulated the expression levels of FASN and SCD enzymes, both at the transcriptional (Fig 3A) and at the post-transcriptional levels (Fig 4A).

We obtained similar results after Yarrow SFE treatment in PANC-1, a pancreatic cancer cell line which has been described to be more chemo and radio-resistant, compared to MIA PaCa-2 cells [87,88]. Fig 3B shows a significant downregulation of the mRNA expression levels of SREBP1, FASN and SCD in PANC-1 pancreatic cancer cell line, and Fig 4B shows a tendency towards a reduction in the protein expression levels of FASN and SCD.
The effect of Yarrow SFE on SREBF1 downregulation seems to be highly specific, as similar results were obtained in other cancer types, such as in SW-620, a colon cancer cell line (S2 Fig).

**Yarrow SFE diminishes intracellular lipid content and cell invasion**

Tumor cell invasion is an important read-out of the aggressiveness and metastatic potential of cancer cells. In this regard, it has been described a link between FASN downregulation and the reduction of invasion in cancer [84,89]. Thus, next we aimed to investigate the ability of Yarrow SFE to affect the invasion capabilities of MIA PaCa-2 cells through Matrigel-coated chambers. After 48 hours of exposition to Yarrow SFE extract, cells which still alive were placed onto a Matrigel chamber and those invading the matrix towards the lower chamber were monitored. Yarrow SFE treatment significantly reduced the number of cells that passed through Matrigel in a dose-dependent manner, with a reduction of the invading cells of a 50% and 80% after treatment with 30 and 70 μg/mL of the extract, respectively, compared to control non-treated cells (DMSO) (Fig 5A). To further assess the impact of Yarrow SFE in intracellular lipid metabolism, we used the Bodipy fluorophore, a specific dye for cellular neutral lipid droplets content. As shown in Fig 5B, MiaPaca-2 treated cells with Yarrow SFE were less prone to neutral lipid droplets accumulation compared to control non-treated cells (DMSO). These results suggest that alterations in lipid homeostasis impact on signaling pathways implicated in invasion.

**Yarrow-SFE inhibits the growth of pancreatic tumor xenografts in athymic nude mice**

As we have previously shown in vitro, antitumoral effects of Yarrow SFE on pancreatic cancer cells reduce cell viability, inhibit tridimensional cell growth, and induce apoptosis [22]. As here we found an inhibition of invasion and a reduced expression of molecular targets implicated in FA and cholesterol homeostasis, we aimed to investigate whether Yarrow SFE could inhibit in vivo the tumor growth of pancreatic cancer cells using a xenograft mouse model.

With this purpose, we injected 1,5x10⁶ of MIA PaCa-2 cells subcutaneously in nude mice. Tumor volume was measured three times per week from the day of inoculation. When tumors reached an average volume of 100 mm³, mice were treated with 1000 mg/kg Yarrow 3 times per week. As shown in Fig 6A, tumor growth was reduced in Yarrow SFE treated animals compared to control animals (corn oil) being statistically significant after 10 days of treatment.

Tumor weights at the end of the experiment showed significant reduced values in Yarrow SFE treated mice compared to control animals (Fig 6B). Importantly, we did not find differences regardless body weights nor liver weights (Fig 6C and 6D).

At the end of the experiment, Yarrow SFE treated mice presented a tumor volume reduction of 28.69% (P < 0.05) compared to the control ones (corn oil). Ki-67 staining showed a decrease in the number of Ki-67 positive cells in the tumors of Yarrow SFE treated mice compared to control ones, indicating a reduction in proliferation of tumor cells (Fig 7A). Importantly, the expression levels of SREBF1 in the tumors of Yarrow SFE treated animals was also significantly reduced compared to control animals (Fig 7B).

**Discussion**

Pancreatic cancer remains one of the most uncontrollable and devastating malignant tumors due to its late diagnosis and chemo-refractory profile.

The altered metabolism in tumoral cells has been highlighted in the last years, being an important part of the metabolic reprogramming found in cancer. Lipids, in addition to their
role as fuels for ATP production, they play a key role as components of plasmatic and organelles membranes, affecting their plasticity, and are also important as cell signaling molecules. Lipid metabolism alterations have been related to an increase in tumor progression and malignancy. In this regard, SREBP proteins, which are master regulators of lipid metabolism, together with FASN and SCD have been found to be upregulated in several neoplasia.

Fig 3. Yarrow SFE inhibits the expression levels of SREBP1 molecular targets FASN and SCD in MIA PaCa-2 and PANC-1 pancreatic cancer cells. (A) mRNA relative expression in human pancreatic cancer-derived MIA PaCa-2 and (B) PANC-1 cells treated 48 hours with different concentrations of Yarrow extract. Data represent the mean ± S.E.M of three independent experiments each one performed in triplicate. Asterisks indicate statistical differences in treated cells compared to control (DMSO) and ***p<0.001; ****p<0.0001.

https://doi.org/10.1371/journal.pone.0214294.g003
Regardless pancreatic cancer, alterations in lipid metabolism have been also described, such as the increase of de novo lipogenesis, which supports tumor growth and malignancy [75,84] and correlates with poorer prognosis in clinics [90].

In this scenario, new approaches to target the altered lipid metabolism in cancer are required to improve cancer patient’s survival. Plant-derived products are a source of bioactive compounds with a reduced toxicity that have great potential in the treatment of chronic diseases conditions including obesity, metabolic syndrome, type 2 diabetes, cardiovascular diseases and cancer [91,92]. Conventional strategies of pharmaceutical industries are focused on isolating pure components as a treatment approach, but plant derived extracts are of great interest because they are composed by several bioactive phytochemicals, as well as because they can act synergistically and target several genes.

In this context, we recently have investigated the antitumoral properties of Yarrow SFE extract (obtained by supercritical fluid extraction -SFE-). Yarrow SFE diminished cell viability of pancreatic cancer cell lines by induction of apoptosis. Moreover, it reduced the ability of these cells to growth and to form colonies in Matrigel. Importantly, Yarrow SFE extract synergized with the antimetabolite 5-fluororacil which is currently used in clinics to treat pancreatic tumors, making the treatment more effective [22].

Herein, by microarray gene expression analysis of MIA PaCa-2 cells treated with Yarrow SFE (at 30 and 70 μg/mL), we identify SREBF1 transcription factor as a direct molecular target.
of the extract. The same tendency is found in another pancreatic cancer cell line, PANC-1, which is has been reported to be a more aggressive [93]. Yarrow SFE targets similarly SREBF1a and SREBF1c isoforms, but do not significantly downregulates the expression of SREBF2.

SREBP1c binds to the promoter of genes such as FASN (Fatty Acid Synthase), SCD (Stearoyl-CoA Desaturase) or ACC (Acetyl-CoA carboxylase) [94–96], which are essential players for de novo synthesis of fatty acids or lipogenesis.

In pancreatic cancer, it has been shown that SREBP1 expression is significantly higher in tumoral tissue compared to adjacent normal tissue. In addition, the aberrant expression of this gene predicts worst prognosis [75]. SREBP1 levels are also increased in other types of cancer, such as prostate, liver, or endometrial tumors, conferring them higher invasion and metastatic capacities [70,73,74]. Thus, SREBP1 has been proposed by several authors as a potential therapeutic target in cancer treatment [82]. In pancreatic cancer cells (PANC-1, PxPC3 and SW1990), SREBP1 silencing reduced proliferation and colony formation. Moreover, SREBF1
silencing diminished the expression of key growth- and apoptosis-regulating genes such as FASN, SCD, TP53, ACC, that results in the decrease of intracellular lipid content and apoptosis [97]. These results are similar to ours after Yarrow SFE treatments, where there is a reduction of SREBF1 expression levels together with an inhibition of invasion and induction of apoptosis (caspase activation). In addition, we have previously shown that Yarrow SFE is more selective against cancer cell lines than normal cells [22]. As cancer cells present higher expression of SREBF1 than normal cells [75], the observed effect of Yarrow SFE on SREBF1 could explain the specificity against tumor cells, being normal cells more protected.

In patients, together with SREBP1, FASN and SCD are also considered worse prognosis markers. These genes are also diminished in MIA PaCa-2 cells after Yarrow SFE treatments.

In the same way, FASN has been shown to be upregulated in several cancers [16,84], including pancreatic cancer [98,99]. High serum levels of FASN are associated with aggressiveness [98,100] and resistance to the chemotherapeutic gemcitabine [101,102].
(A) Xenograft Tumors/Ki-67

![Graph showing Ki-67 levels in control and yarrow-treated groups.](image)

Control (corn oil) vs Yarrow (1000 mg/kg)

(B) Xenograft Tumors/SREBF1

![Graph showing SREBF1 mRNA levels in control and yarrow-treated groups.](image)

Control vs Yarrow (*)
Conversely, FASN inhibition have been shown to decrease tumor growth and to drive apoptotic cell death. These cytotoxic and cytostatic effects have been validated in ovarian, prostate and pancreatic cancers [98,103,104]. In addition, FASN pharmacological blockage also synergizes with 5-fluorouracil [105] to enhance apoptosis activation [76,106]. In this sense, our results match with previous ones, where Yarrow SFE extract could act as a FASN inhibitor.

Finally, regarding SCD, which catalyzes the rate limiting step in the production of monounsaturated fatty acids (MUFAs), whose levels are directly associated with replication rates in cancer cells [107]. High levels of SCD have been described to increase cell proliferation and survival in pancreatic tumors [107,108], and its inhibition has been shown to brake tumor growth in lung, colorectal, osteosarcoma and breast tumors [65–67]. Thus, being considered as a target for chemotherapy, SCD therapeutic inhibition affects tumor growth in several xenograft models (prostate, kidney, gastric or ovarian tumor [68,69].

In the context of the use of phytochemicals for cancer treatment through a metabolic approach, genistein and ginkgolic acid have already been demonstrated to induce cytotoxicity by downregulating of SREBP1 [71,109]. Promising results have been obtained by luteolin, which also targets FASN [76].

Herein, we demonstrate that Yarrow SFE inhibits SREBF1, FASN and SCD leading to less accumulation of lipid droplets which also correlates with the inhibition of cell invasion. Further studies are needed to better understand how Yarrow SFE could disrupt cell metabolism and/or cell bioenergy through metabolomic approaches and cell bioenergetics flux analysis.

Importantly, we demonstrate the in vivo effect of Yarrow SFE inhibiting the tumor growth of xenograft models, which seems to be mediated, at least partially, by the downregulation of SREBP1.

In this sense, our data suggest that Yarrow SFE can be proposed as a complementary adjuvant or nutritional complement in pancreatic cancer therapy.

Conclusions
Yarrow SFE decreases pancreatic cancer cell proliferation and invasion. We identify SREBF1 together with FASN and SCD, as molecular targets of Yarrow SFE. We also demonstrate the in vivo effect of Yarrow SFE, which brakes tumor growth in a xenograft mouse model of pancreatic cancer, together with SREBF1 downregulation in the injected tumors. Our data suggest that Yarrow SFE can be proposed as a complementary adjuvant or nutritional supplement in pancreatic cancer therapy.

Supporting information

S1 Fig. Intracellular cholesterol levels. Relative intracellular cholesterol levels in human pancreatic cancer-derived MIA PaCa-2 (A) cells treated 48 hours two with different concentrations of Yarrow SFE extract. Data represent the mean ± S.E.M of three independent experiments each one performed in triplicate.

S2 Fig. Yarrow inhibits the expression of SREBF1 in SW620 colon cancer cells. Line. mRNA relative expression of SREBF1 in SW620 cells treated 48 hours with different
concentrations of Yarrow extract compared to non-treated control cells (DMSO). Data represent the mean ± S.E.M of three independent experiment each one performed in triplicate. Asterisks indicate statistical differences in treated cells with respect to the control (non-treated cells) and *p<0.05; **p<0.01; ***p<0.001.

(TIF)

Acknowledgments
We thank Dr. Jean-Baptiste Demoulin for having provided us the anti-SCD1 antibody.

Author Contributions
Conceptualization: Lamia Mouhid, Marta Gómez de Cedrón, Guillermo Reglero, Tiziana Fornari, Ana Ramírez de Molina.

Formal analysis: Lamia Mouhid.

Investigation: Lamia Mouhid, Marta Gómez de Cedrón.

Methodology: Lamia Mouhid, Marta Gómez de Cedrón.

Resources: Elena García-Carrascosa.

Supervision: Marta Gómez de Cedrón, Ana Ramírez de Molina.

Writing – original draft: Lamia Mouhid, Marta Gómez de Cedrón.

References
1. Michaud DS. Epidemiology of Pancreatic Cancer. Springer; 2017. pp. 471–487.
2. Gordon-Dseagu VL, Devesa S, Goggins M, Stolzenberg-Solomon R. No Title. Pancreatic cancer Incidence Trends Recent patterns overall by Histol type among US men women by racial/ethnic Group from Surveillance, Epidemiol End Results Progr. 2017;
3. Sun Y-J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003; 3: 768–780. https://doi.org/10.1038/nrc1189 PMID: 14570043
4. Mouhid L, Corzo-Martínez M, Torres C, Vázquez L, Reglero G, Fornari T, et al. Improving In Vivo Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems. J Oncol. 2017;2017.
5. Kotecha R, Takami A, Espinoza JL. Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget. 2016; 7: 52517–52529. https://doi.org/10.18632/oncotarget.9593 PMID: 27232756
6. Gonzalez-Vallinas M, Gonzalez-Castejon M, Rodriguez-Casado A, de Molina AR. Dietary phytochemicals in cancer prevention and therapy: a complementary approach with promising perspectives. Nutr Rev. 2013; 71: 585–599. https://doi.org/10.1111/nure.12051 PMID: 24032363
7. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005; 100: 72–79. https://doi.org/10.1016/j.ejp.2005.05.011 PMID: 16009521
8. Ouyang L, Luo Y, Tian M, Zhang S, Lu R, Wang J, et al. Plant natural products: from traditional compounds to new emerging drugs in cancer therapy. Cell Prolif. 2014; 47: 506–515. https://doi.org/10.1111/cpr.12143 PMID: 25377084
9. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605–1617. https://doi.org/10.1056/NEJMa0901557 PMID: 20427809
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230
11. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7: 11–20. https://doi.org/10.1016/j.cmet.2007.10.002 PMID: 18177721
12. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013; 123: 3678–3684. https://doi.org/10.1172/JCI69600 PMID: 23999442
13. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death Dis. 2014; 5: e1065. https://doi.org/10.1038/cddis.2014.38 PMID: 2456680

14. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010; 35: 427–433. https://doi.org/10.1016/j.tibsc.2010.05.003 PMID: 20570523

15. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953; 13: 27–29. PMID: 13032945

16. Currie E, Schulze A, Zechner R, Walther TC, Farese RV. Cellular fatty acid metabolism and cancer. Cell Metab. 2013; 18: 153–161. https://doi.org/10.1016/j.cmet.2013.05.017 PMID: 23791484

17. Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Gonzalez-Vallinas M, et al. ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients. Oncotarget. 2015; 6: 7348–7363. https://doi.org/10.18632/oncotarget.3130 PMID: 25749516

18. Fan TWM, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer disclosed by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009; 8: 41. https://doi.org/10.1186/1476-4589-8-41 PMID: 19558692

19. Beloribi-Djefal S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016; 5: e189. https://doi.org/10.1038/oncogenesis.2015.49 PMID: 26807844

20. Peck B, Schulze A. Lipid desaturation–the next step in targeting lipogenesis in cancer? FEBS J. 2016; 283: 2767–2778. https://doi.org/10.1111/febs.13881 PMID: 26881383

21. García-Risco MR, Mouhid L, Salas-Pérez L, López-Padilla A, Santoyo S, Jaime L, et al. Biological Activities of Asteraceae (Achillea millefolium and Calendula officinalis) and Lamiaceae (Melissa officinalis and Origanum majorana) Plant Extracts. Plant Foods Hum Nutr. 2017; 72: 96–102. https://doi.org/10.1007/s11130-016-0596-8 PMID: 28101823

22. Mouhid L, de Cedrón MG, Vargas T, García-Carrascosa E, Muñoz NH, García-Risco MR, et al. Identification of antitumoral agents against human pancreatic cancer cells from Asteraceae and Lamiaceae plant extracts. 2018; BMC Compl. https://doi.org/10.1186/s12906-018-2322-6 PMID: 30223811

23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. methods. 2001; 25: 402–408. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609

24. Demoulin JB, Ericsson J, Kallin A, Ronnstrand L, Heldin CH. Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J Biol Chem. 2004; 279: 35392–35402. https://doi.org/10.1074/jbc.M405924200 PMID: 15213220

25. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 2009; 69: 700–708. https://doi.org/10.1158/0008-5472.CAN-08-3157 PMID: 19147587

26. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013; 45: 251–262. https://doi.org/10.1016/j.crt.2013.45.4.251 PMID: 24453997

27. Sullivan LB, Gui DY, Heiden MG Vander. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer. 2016; 16: 680–693. https://doi.org/10.1038/nrc.2016.85 PMID: 27658530

28. Bowles TL, Kim R, Galanese J, Parsons CM, Virudachalam S, Kung H, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J cancer. 2008; 123: 1950–1955. https://doi.org/10.1002/ijc.23723 PMID: 18661517

29. Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, et al. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. BMC Cancer. 2014; 14: 1. https://doi.org/10.1186/1471-2407-14-1

30. Qiu F, Huang J, Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett. 2015; 364: 1–7. https://doi.org/10.1016/j.canlet.2015.04.020 PMID: 25917076

31. Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur GM. Role of CHD5 in human cancers: 10 years later. Cancer Res. 2014; 74: 652–658. https://doi.org/10.1158/0008-5472.CAN-13-3056 PMID: 24419087

32. Bagchi A, Papazoglou C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36. Cell. 2007; 128: 459–475. https://doi.org/10.1016/j.cell.2006.11.052 PMID: 17289567

33. Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B, et al. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung cancer. 2012; 76: 324–331. https://doi.org/10.1016/j.lungcan.2011.11.019 PMID: 22186629

34. Hall WA, Petrova A V, Colbert LE, Hardy CW, Fisher SB, Saka B, et al. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy
for resected pancreatic cancer. Oncogene. 2014; 33: 5450–5456. https://doi.org/10.1038/onc.2013.488 PMID: 24276239

35. Zhang R, Thamm DH, Misra V. The effect of Zhangfei/CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines. BMC Vet Res. 2015; 11: 1. https://doi.org/10.1186/s12917-014-0312-6 PMID: 25582057

36. López-Mateo I, Villaronga MÁ, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

37. Zhang R, Thamm DH, Misra V. The effect of Zhangfei /CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines. BMC Vet Res. 2015; 11: 1. https://doi.org/10.1186/s12917-014-0312-6 PMID: 25582057

38. Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A. Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J Biol Chem. 2013; 288: 608–618. https://doi.org/10.1074/jbc.M112.425736 PMID: 23166327

39. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

40. Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A. Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J Biol Chem. 2013; 288: 608–618. https://doi.org/10.1074/jbc.M112.425736 PMID: 23166327

41. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

42. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

43. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

44. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

45. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

46. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

47. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

48. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

49. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

50. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008

51. Beletza B, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012; 11: 3887–3895. https://doi.org/10.4161/cc.22133 PMID: 22983008
53. Kammerer S, Roth RB, Reneland R, Marnello G, Hoyal CR, Markward NJ, et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res. 2004; 64: 8906–8910. 64/24/8906 [pii] https://doi.org/10.1158/0008-5472.CAN-04-1788 PMID: 15604251

54. Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R, El-Naggar AK. ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol. 2005; 41: 580–588. https://doi.org/10.1016/j.oraloncology.2005.01.002 PMID: 15975520

55. Gunduz M, Beder LB, Gunduz E, Nagatsuka H, Fukushima K, Pehlivan D, et al. Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci. 2008; 99: 531–538. https://doi.org/10.1111/j.1349-7006.2007.00708.x PMID: 18081876

56. Doyon Y, Cayrou C, Ullah M, Landry A-J, Côte V, Selleck W, et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell. 2006; 21: 51–64. https://doi.org/10.1016/j.molcel.2005.12.007 PMID: 16387653

57. Zhang M, Truscott J, Davie J. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Mol Cancer. 2013; 12: 1. https://doi.org/10.1186/1476-4598-12-1

58. Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer Res. 2014; 74: 1452–1462. https://doi.org/10.1158/0008-5472.CAN-13-2171 PMID: 24390737

59. Song L, Li D, Zhao Y, Gu Y, Zhao D, Li X, et al. miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression. Tumor Biol. 2016; 37: 2891–2900.

60. Turk CM, Fagans-Kilpatrick KD, Williams KE, Gozgit JM, Smith-Schneider S, Marconi SA, et al. Paralemin-1 is over-expressed in estrogen-receptor positive breast cancers. Cancer Cell Int. 2012; 12: 1. https://doi.org/10.1186/1475-2867-12-1

61. Albrecht I, Bieri R, Leu A, Granacher P, Hagmann J, Kiliman MW, et al. Paralemin-1 is expressed in lymphatic endothelial cells and modulates cell migration, cell maturation and tumor lymphangiogenesis. Angiogenesis. 2013; 16: 795–807. https://doi.org/10.1007/s10456-013-9356-7 PMID: 23709172

62. Albrecht I, Bieri R, Leu A, Granacher P, Hagmann J, Kiliman MW, et al. Paralemin-1 is expressed in lymphatic endothelial cells and modulates cell migration, cell maturation and tumor lymphangiogenesis. Angiogenesis. 2013; 16: 795–807. https://doi.org/10.1007/s10456-013-9356-7 PMID: 23709172

63. Subramani D, Alahari SK. Integrin-mediated function of Rab GTPases in cancer progression. Mol Cancer. 2010; 9: 1. https://doi.org/10.1186/1476-4598-9-1

64. Kloth JN, Gorter A, Fleuren GJ, Oosting J, Uljee S, Haar N Ter, et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 2008; 215: 222–230. https://doi.org/10.1002/path.2347 PMID: 18438953

65. Dimberg J, Ström K, Löfgren S, Zar N, Hugander A, Matussek A. Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas. Oncol Lett. 2011; 2: 413–418. https://doi.org/10.3892/ol.2011.280 PMID: 22866096

66. Choi KY, Cho YJ, Kim JS, Ahn Y-H, Hong SH. SHC1 sensitizes cancer cells to the 8-Cl-cAMP treatment. Biochem Biophys Res Commun. 2015; 463: 673–678. https://doi.org/10.1016/j.bbrc.2015.05.123 PMID: 26043699

67. Hamada S, Masamune A, Miura S, Satoh K, Shimosegawa T. MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal. 2014; 26: 179–185. https://doi.org/10.1016/j.cellsig.2013.11.003 PMID: 24216611

68. Kuranami S, Yokobori T, Mogi A, Altan B, Yazima T, Onozato R, et al. Src kinase-associated phosphoprotein2 expression is associated with poor prognosis in non-small cell lung cancer. Anticancer Res. 2015; 35: 2411–2415. 35/4/2411 [pii] PMID: 25862907

69. Tanaka M, Shimamura S, Kuriyama S, Maeda D, Goto A, Alba N. SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression. Cancer Res. 2016; 76: 358–369. https://doi.org/10.1158/0008-5472.CAN-15-1879 PMID: 26577701

70. Harada T, Chelala C, Bhakta V, Chaplin T, Cauze B, Karil P, et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene. 2008; 27: 1951–1960. https://doi.org/10.1038/sj.onc.1210832 PMID: 17952125

71. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res. 2012; 10: 133–142. https://doi.org/10.1158/1541-7786.MCR-11-0206 PMID: 22064655

72. Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, et al. Inhibition of SREBP1 sensitizes cells to death ligands. Oncotarget. 2011; 2: 186–196. https://doi.org/10.18632/oncotarget.239 PMID: 21406729
72. Lin L, Zheng X, Qiu C, Dongol S, Lv Q, Jiang J, et al. SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis. Oncol Rep. 2014; 32: 2831–2835. https://doi.org/10.3892/or.2014.3521 PMID: 25270091

73. Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, et al. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell cycle. 2012; 11: 2348–2358. https://doi.org/10.4161/cc.20811 PMID: 22672904

74. Li C, Yang W, Zhang J, Yao Y, Tu K, et al. SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma. Int J Mol Sci. 2014; 15: 7124–7138. https://doi.org/10.3390/ijms15057124 PMID: 24776759

75. Sun Y, He W, Luo M, Zhou Y, Chang G, Ren W, et al. SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism. Tumor Biol. 2015; 1–9. https://doi.org/10.1007/s13277-015-3047-5 PMID: 25589463

76. Li J, Gu D, Lee SSY, Song B, Bandyopadhyay S, Chen S, et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene. 2016;

77. Xing Y, Meng Q, Chen X, Zhao Y, Liu W, Hu J, et al. TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget. 2016; https://doi.org/10.18632/oncotarget.8586 PMID: 24930919

78. Kashimoto K, Komatsu S, Ichikawa D, Arita T, Konishi H, Nagata H, et al. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. Cancer Sci. 2012; 103: 2021–2026. https://doi.org/10.1111/j.1349-7006.2012.02407.x PMID: 22862969

79. Ong CA, Shannon NB, Ross-Innes CS, O’Donovan M, Rueda OM, Hu DE, et al. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. 2014; 106: 10.1093/jnci/dju050. https://doi.org/10.1093/jnci/dju050 PMID: 25589463

80. Horton JD, Goldstein JL, Brown MS. SREBP-1c: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125–1131. https://doi.org/10.1172/JCI15593 PMID: 24777112

81. Eberle D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004; 86: 839–848. https://doi.org/10.1016/j.biochimi.2004.09.018 PMID: 15589694

82. Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des. 2014; 20: 2619–2626. PMID: 23859617

83. Cruz PM, Mo H, Conchon WJ, Sabnis N, Lacko AG. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol. 2013; 4: 119. https://doi.org/10.3389/fphar.2013.00119 PMID: 24093019

84. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev. 2007; 7: 763.

85. Fleischmann M, Lynedjian PB. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J. 2000; 349: 13–17. PMID: 10861205

86. Dang C V. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 2010; 70: 859–862. https://doi.org/10.1158/0008-5472.CAN-09-3556 PMID: 20086171

87. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, et al. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol. 2011; 2: 89–98. PMID: 21331354

88. Asanuma K, Morii R, Yajima T, Yaghashi A, Yamada M, Kobayashi D, et al. Survivin as a radioresistance factor in pancreatic cancer. Cancer Sci. 2000; 91: 1204–1209.

89. Long XH, Mao JH, Peng AF, Zhou Y, Huang SH, Liu ZL. Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp Ther Med. 2013; 5: 1048–1052. https://doi.org/10.3892/etm.2013.959 PMID: 23599729

90. Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2380–2385. https://doi.org/10.1158/1055-9965.EPI-09-0144 PMID: 19723916

91. Zhang Y-J, Gan R-Y, Li S, Zhou Y, Li A-N, Xu D-P, et al. Antioxidant phytochemicals for the prevention and treatment of chronic diseases. Molecules. 2015; 20: 21138–21156. https://doi.org/10.3390/molecules20121975 PMID: 26633317

92. Zhang A, Sun H, Wang X. Recent advances in natural products from plants for treatment of liver diseases. Eur J Med Chem. 2013; 63: 570–577. https://doi.org/10.1016/j.ejmech.2012.12.062 PMID: 23567947
93. Yin T, Wei H, Gou S, Shi P, Yang Z, Zhao G, et al. Cancer stem-like cells enriched in panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci. 2011; 12: 1595–1604. https://doi.org/10.3390/ijms12031595 PMID: 21673909

94. Choi WI, Jeon BN, Park H, Yoo JY, Kim YS, Koh DI, et al. Proto-oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J Biol Chem. 2008; 283: 29341–29354. https://doi.org/10.1074/jbc.M802477200 PMID: 18682402

95. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013; 1: 3. https://doi.org/10.1186/2049-3002-1-3 PMID: 24280005

96. Oh SY, Park SK, Kim JW, Ahn YH, Park SW, Kim KS. Acetyl-CoA carboxylase beta gene is regulated by sterol regulatory element-binding protein-1 in liver. J Biol Chem. 2003; 278: 28410–28417. https://doi.org/10.1074/jbc.M300553200 PMID: 12764144

97. Sekar S, Gopalakrishnan V, Taghibiglou C. Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. Biochem Biophys Res Commun. 2017; 488: 136–140. https://doi.org/10.1016/j.bbrc.2017.05.023 PMID: 28483521

98. Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014; 20: 2279–2303. https://doi.org/10.3748/wjg.v20.i9.2279 PMID: 24605027

99. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, et al. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol. 2011; 2: 89–98. PMID: 21331354

100. Wu X, Qin L, Fako V, Zhang J-T. Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments. Adv Biol Regul. 2014; 54: 214–221. https://doi.org/10.1016/j.bior.2013.09.004 PMID: 24080588

101. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 2001; 61: 1493–1499. PMID: 11245456

102. Vazquez-Martín A, Ropero S, Brunet J, Colomer R, Menendez JA. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol Rep. 2007; 18: 973–980. PMID: 17786362

103. Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HCF, et al. Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Investig. 2011; 91: 232–240. https://doi.org/10.1038/latinvest.2010.157 PMID: 20805790

104. Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 2010; 31: 1509–1515. https://doi.org/10.1093/carcin/bgp1131 PMID: 20595235

105. Macášek J, Vecka M, Žák A, Urbánek M, Krechler T, Petruželka L, et al. Plasma fatty acid composition in patients with pancreatic cancer: correlations to clinical parameters. Nutr Cancer. 2012; 64: 946–955. https://doi.org/10.1080/01635581.2012.716138 PMID: 23061902

106. Nie L-Y, Lu Q-T, Li W-H, Yang N, Dongol S, Zhang X, et al. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncol Rep. 2013; 30: 1346–1354. https://doi.org/10.3892/or.2013.2675 PMID: 23818099